This agreement allows Recepta Biopharma to use the PER.C6 technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research.
Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.